Program
tucidinostat
Also written as “Chidamide”, “Tucidinostat” and “HBI-8000”.
Its studies are mostly in Lymphoma, T-Cell, Peripheral · Carcinoma, Non-Small-Cell Lung · Melanoma · Breast Neoplasms · Lymphoma, Non-Hodgkin, led by 4 companies.
Drug pageTucidinostat: every studyAll 185 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Chipscreen Biosciences | 92 open or running | phase 3since Jun 17, 2015 | Apr 12, 2013 | May 31, 2028phase 3 · NCT06497985 |
| HUYABIO International, LLC.its history only | 71 open or running | phase 3since Dec 7, 2020 | Oct 5, 2015 | none ahead |
| Great Novel Therapeutics Biotech & Medicalsits history only | 21 open or running | phase 2since Feb 7, 2023 | Feb 7, 2023 | Jun 2027phase 2 · NCT05833724 |
| Jiangsu HengRui Medicineits history only | 11 open or running | phase 3since Nov 5, 2023 | Nov 5, 2023 | none ahead |
Also a collaborator on its studies: Bristol-Myers Squibb and Iqvia Pty.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Chipscreen Biosciences only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Apr 12, 2013First study: phase 2 study in Carcinoma, Non-Small-Cell LungFirst studyNCT01836679 · 124 enrolled · China
- Jun 17, 2015Phase 3 study in Breast NeoplasmsNCT02482753 · 365 enrolled · China
- Jun 9, 2016Named tucidinostatINNProposed as its International Nonproprietary Name in WHO's List 115 · before, HBI-8000
- Jun 17, 2016Phase 1 study in Lymphoma, T-Cell, PeripheralNCT02809573 · 30 enrolled · China
- May 30, 2019Phase 2 study in Lymphoma, Non-HodgkinNCT03974243 · 9 enrolled · China
- Jan 14, 2020Phase 3 study in Lymphoma, Large B-Cell, DiffuseNCT04231448 · 423 enrolled · China
- Sep 27, 2021Phase 2 study in Carcinoma, Non-Small-Cell LungNCT05068427 · 34 enrolled · China
- Aug 23, 2022Phase 2 study in Carcinoma, Non-Small-Cell LungNCT05519865 · 118 enrolled · China
- Jun 28, 2024Phase 3 study in Colorectal NeoplasmsNCT06497985 · 430 planned · China
- Apr 25, 2025Phase 3 study in Lymphoma, T-Cell, PeripheralNCT06947967 · 224 planned · China
Ahead
- May 31, 2028Primary completion: phase 3 study in Colorectal NeoplasmsNCT06497985
- Dec 2032Primary completion: phase 3 study in Lymphoma, T-Cell, PeripheralNCT06947967
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 9 Chipscreen Biosciences leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06947967Lymphoma, T-Cell, Peripheral · China | 3 | Recruiting | Dec 2032 | 224 |
| NCT06497985Colorectal Neoplasms · China | 3 | Recruiting | May 31, 2028 | 430 |
| NCT05519865Carcinoma, Non-Small-Cell Lung · China | 2 | Completed | Nov 18, 2024 | 118 |
| NCT05068427Carcinoma, Non-Small-Cell Lung · China | 2 | Completed | Feb 23, 2023 | 34 |
| NCT04231448Lymphoma, Large B-Cell, Diffuse · China | 3 | Completed | Jan 10, 2023 | 423 |
| NCT03974243Lymphoma, Non-Hodgkin · China | 2 | Completed | Dec 31, 2021 | 9 |
| NCT02809573Lymphoma, T-Cell, Peripheral · China | 1 | Completed | Jan 8, 2019 | 30 |
| NCT02482753Breast Neoplasms · China | 3 | Completed | Mar 2018 | 365 |
| NCT01836679Carcinoma, Non-Small-Cell Lung · China | 2 | Completed | May 2015 | 124 |
How it is read
Names in the registry
- “Chidamide”, 7 entries
- “Tucidinostat”, 4 entries
- “HBI-8000”, 4 entries
- “HBI-8000 in combination with nivolumab”, 2 entries
- “SHR2554 analog tablets; Chidamide”, 1 entry
Conditions, from the studies’ own filings
- Lymphoma, T-Cell, Peripheral, 4 studies
- Carcinoma, Non-Small-Cell Lung, 4 studies
- Melanoma, 2 studies
- Breast Neoplasms, 2 studies
- Lymphoma, Non-Hodgkin, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.